Enterin
PrivateLast Round
Series A
Jul 17, 2017
Total Funding Raised
$12.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Enterin operates in Healthcare & Life Sciences and is based in Philadelphia, Pennsylvania. Its latest recorded funding round was a Series A round in July 2017.
Enterin is a biotechnology company that develops novel drugs designed to offer treatments that target the gut-brain axis and modify the course of neurodegenerative disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enterin Comparables
Compare Enterin with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vertero Therapeutics | 86% | |
| Stellate Therapeutics Inc. | 86% | |
| Kallyope | 77% |
For institutional investors. Book with your work email.
Enterin Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Enterin Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Scientia Ventures | Series A, VC Round |
| The Naissos Group | Series A, VC Round |
| Indie Asset Partners | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased from 0 to 7, representing 50% of headcount.
- Nov 10, 2024
Monthly visitors grew 1000% MoM, from 70 to 770.
For institutional investors. Book with your work email.
Enterin Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Enterin's valuation, stock price, and market status.
Is Enterin a public or private company?
Enterin is a private company.
What is the current stock price of Enterin?
Enterin is a private company, so its shares have no public market price. Caplight tracks Enterin's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Enterin worth (valuation)?
Valuation information for Enterin is not publicly available.
Can I buy Enterin stock?
Enterin shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Enterin's last funding round?
Enterin's most recent funding round was Series A on July 17, 2017.
Who are the main investors in Enterin?
Key investors in Enterin include Scientia Ventures, The Naissos Group, Indie Asset Partners.
Will Enterin IPO soon?
No public IPO plans have been announced for Enterin.
How can I track Enterin secondary market activity?
Caplight tracks bids, offers, and trades in Enterin's shares on secondary markets.